STOCK TITAN
  1. Home
  2. Sec-filings
  3. CERO
  4. [8-K] CERo Therapeutics Holdings, Inc. Reports Material Event

[8-K] CERo Therapeutics Holdings, Inc. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K

Filing content is currently unavailable.

Source: View Original Filing on SEC EDGAR

Stock CERO logo
CERo Therapeutics

NASDAQ:CERO

CERO Rankings

#6072 Ranked by Market Cap
N/A Ranked by Dividends

CERO Latest News

Jul 31, 2025
CERo Therapeutics Doses Second Acute Myeloid Leukemia Patient with CER-1236
Jun 23, 2025
CERo Therapeutics Holdings, Inc. Announces First Patient Completes Dose-Limiting Toxicity Observation Period with No Reported DLTs in Phase 1 Trial of CER-1236
Jun 17, 2025
CERo Therapeutics Holdings, Inc. Announces FDA Orphan Drug Designation Granted to CER-1236 for the Treatment of Acute Myeloid Leukemia (AML)
Jun 11, 2025
CERo Therapeutics Holdings, Inc. Announces Reverse Stock Split
Jun 6, 2025
CERo Therapeutics, Inc. Announces Option Exercise for Additional Series D Financing

CERO Latest SEC Filings

Aug 22, 2025
[10-Q] CERo Therapeutics Holdings, Inc. Quarterly Earnings Report
Aug 15, 2025
[NT 10-Q] CERo Therapeutics Holdings, Inc. SEC Filing
Aug 14, 2025
[SCHEDULE 13G/A] CERo Therapeutics Holdings, Inc. SEC Filing
Jul 28, 2025
[S-8] CERo Therapeutics Holdings, Inc. Employee Benefit Plan Registration
Jul 21, 2025
[S-1] CERo Therapeutics Holdings, Inc. Files IPO Registration Statement

CERO Stock Data

9.47M
483.88k
8.28%
47.92%
4.11%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
SOUTH SAN FRANCISCO